Johnson & Johnson : Janssen Marks First Approval Worldwide f

BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®... | April 21, 2023

Related Keywords

Beerse , Region Flamande , Belgium , Italy , Germany , France , Spain , United Kingdom , London , City Of , Japan , Janssen Cilag Gmb , Martin Vogel , Magda Palhota , Peter Lebowitz , Gerhardt Attard , Janssen Cilag Gm , Urology Care Foundation , Exchange Commission , Drug Administration , Companies Of Johnson , Janssen Research Development , European Medicines Agency , University College London , None Of The Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies , Johnson , Tesaro Inc , European Commission , Janssen Pharmaceutical Companies Of Johnson , Drug Administration Seeking Approval Of Niraparib , European Union , Janssen Cilag International , Janssen Biotech Inc , Professor Gerhardt Attard , Area Lead Oncology , Hazard Ratio , Confidence Interval , Global Therapeutic Area Head , Janssen Research , New Drug Application , Janssen Biotech , European Economic Area , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Janssen Pharmaceutica , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Advanced Prostate Cancera Review , Current Therapies , Cold Spring Harb Perspect , Genomic Profiling , Literature Review , Advanced Prostate Cancer , Associated Homologous Recombination Repair Gene , Prospective Cohort Study , Prostate Cancer , Indolent Prostate Cancer , Early Age , Combination With Abiraterone Acetate , Prednisone Versus Abiraterone Acetate , Participants With Metastatic Prostate Cancer , With Abiraterone Acetate , Homologous Recombination Repair Gene Alterations , Second Interim Analysis , Abiraterone Acetate , Metastatic Castration Resistant Prostate , Janssen Submits New Drug Application , Drug Administration Seeking Approval , Abiraterone Acetate Dual Action Tablet , Plus Prednisone , First Line Targeted Treatment , Metastatic Castration Resistant Prostate Cancer , Participants With Deleterious Germline , Somatic Homologous Recombination Repair , Enters Worldwide Collaboration , License Agreement , What You Should , World Treatment Patterns , Johnson Stock Exchange , News , Information , Press Release , 1 , Pril , 023 , The , Janssen , Harmaceutical , Companies , F , Nnounced , Oday , Hat , European , Commission , Gas , Granted , Marketing , Authorisation , Or Jnj Us4781601046 ,